Conclusions
Erenumab and galcanezumab reduced mean headache days, acute migraine specific medication days, Headache Impact Test score, Migraine Disability Assessment Test score and Visual Analogue Scale score after 3 and 6 doses in real-world patients diagnosed with chronic or episodic migraine who previously did not respond to, at least, three different oral preventive therapies.
Erenumab and galcanezumab exhibit a great safety profile, rarely leading to discontinuation because of poor tolerance. Nevertheless, further studies in real world setting are required since the adverse events are frequent and though mild, some can lead to treatment interruption.
Erenumab and galcanezumab reduced by a half the number of acute migraine specific medication days in, at least, a 50% of the patients enrolled in this study. Therefore, both monoclonal antibodies seem to be promising therapeutic options even in patients with difficult-to-treat migraine.